JÃ¸rgen Agnholt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8532581/publications.pdf

Version: 2024-02-01

24	570	933264 10	752573 20
papers	citations	h-index	g-index

24	24	24	1243
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Paediatric Crohnâ€™s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. GastroHep, 2022, 2022, 1-11.	0.3	0
2	Effectiveness of infliximab treatment of complex idiopathic anal fistulas. Scandinavian Journal of Gastroenterology, 2021, 56, 391-396.	0.6	1
3	Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohnâ€™s Disease during One-Year Follow-Up. Nutrients, 2021, 13, 1083.	1.7	12
4	Effectiveness of interdisciplinary combined dermatologyâ€“gastroenterologyâ€“rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. BMJ Open, 2021, 11, e041871.	0.8	8
5	Reply. Gastroenterology, 2021, 161, 2068-2069.	0.6	0
6	Decrease in Mucosal IL17A, IFNÎ³ and IL10 Expressions in Active Crohnâ€™s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab. Nutrients, 2020, 12, 3699.	1.7	11
7	Letter: postâ€infective bile acid malabsorption and diarrhoea. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 110-111.	1.9	0
8	The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis. BMC Gastroenterology, 2019, 19, 83.	0.8	10
9	Efficacy of Injection of Freshly Collected Autologous Adipose Tissue Into Perianal Fistulas in Patients With Crohnâ€™s Disease. Gastroenterology, 2019, 156, 2208-2216.e1.	0.6	72
10	Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. European Journal of Gastroenterology and Hepatology, 2019, 31, 964-967.	0.8	3
11	Letter: longâ€term treatment of severe bile acid diarrhoeaâ€”obeticholic acid can normalise SeHCAT retention. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 1034-1035.	1.9	0
12	Effects of Anti-TNFÎ±Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohnâ€™s Disease. Mediators of Inflammation, 2018, 2018, 1-7.	1.4	2
13	Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. Immunopharmacology and Immunotoxicology, 2018, 40, 446-460.	1.1	30
14	Immune responses and parasitological observations induced during probiotic treatment with medicinal Trichuris suis ova in a healthy volunteer. Immunology Letters, 2017, 188, 32-37.	1.1	22
15	Vitamin D increases programmed death receptor-1 expression in Crohnâ€™s disease. Oncotarget, 2017, 8, 24177-24186.	0.8	26
16	Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study. European Journal of Clinical Investigation, 2016, 46, 555-563.	1.7	25
17	Reduced numbers of mucosal DR^{int}macrophages and increased numbers of CD103⁺dendritic cells during anti-TNF-Î± treatment in patients with Crohnâ€™s disease. Scandinavian Journal of Gastroenterology, 2016, 51, 692-699.	0.6	25
18	Effects of Arabinoxylan and Resistant Starch on Intestinal Microbiota and Short-Chain Fatty Acids in Subjects with Metabolic Syndrome: A Randomised Crossover Study. PLoS ONE, 2016, 11, e0159223.	1.1	123

#	Article	IF	Citations
19	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	10
20	Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study. American Journal of Gastroenterology, 2014, 109, 1749-1756.	0.2	81
21	The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-Î± therapy. Journal of Crohn's and Colitis, 2014, 8, 521-528.	0.6	9
22	Increased production of granulocyteâ€“macrophage colony-stimulating factor in Crohn's disease â€“ a possible target for infliximab treatment. European Journal of Gastroenterology and Hepatology, 2004, 16, 649-655.	0.8	39
23	The effect of etanercept and infliximab on the production of tumour necrosis factor Î±, interferon-Î³ and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine, 2003, 23, 76-85.	1.4	55
24	T-cell vaccination in Crohn's disease: principles and presentation of the first two cases. Cytokines, Cellular & Molecular Therapy, 2002, 7, 117-123.	0.3	6